Skip to main content
PLOS One logoLink to PLOS One
. 2023 Jan 20;18(1):e0280269. doi: 10.1371/journal.pone.0280269

Face mask ownership/utilisation and COVID-19 vaccine hesitancy amongst patients recovering from COVID-19 in Cameroon: A cross-sectional study

Frederick Nchang Cho 1,2,*,#, Yayah Emerencia Ngah 3,#, Andrew N Tassang 4,5,6, Celestina Neh Fru 6,7, Peter Canisius Kuku Elad 1,8,#, Patrick Kofon Jokwi 1,#, Valmie Ngassam Folefac 9,10, Ismaila Esa 1, Paulette Ngum Fru 11,12
Editor: Muhammad Shahzad Aslam13
PMCID: PMC9858007  PMID: 36662746

Abstract

Introduction

This study aimed to establish pre-/post Coronavirus Disease 2019 (COVID-19) diagnosis/treatment symptoms, ownership/utilisation of face masks (FMs), as well as vaccine hesitancy (VH) amongst patients recovering from COVID-19.

Methods

A cross-sectional survey was conducted from April - October 2021. Data was collected with structured self-administered questionnaires. Multinomial regression was used to determine associations between ownership/utilisation of FMs with respondents’ characteristics.

Results

Unproductive cough and fatigue were prevalent before and after treatment. Pre-/Post COVID-19 symptoms severity ranged from mild to moderate. There was a COVID-19 VH rate of 492 (74%). The prevalence of FM ownership and utilisation were, respectively, 613 (92.2%) and 271 (40.8%). One main factor was associated with FM ownership; respondent’s sex (p; 5.5x10-2, OR; 0.5, 95%C.I; 0.3 – 1.0). The main reasons for irregular utilisation were; inability to be consistent, only used outdoors, and boredom.

Conclusion

The treatment of COVID-19 does not mean immediate recovery as mild to moderate grade severity still persists. Face mask availability and ownership does not mean appreciable utilisation. This study advocates for an intensification of COVID-19 preventive practices, as well as elaborate education on the importance of vaccination.

Introduction

A novel enveloped ribonucleic acid (RNA) beta (β) corona virus, Coronavirus Disease 2019 (COVID-19) has spread widely from Wuhan, causing tens of thousands of deaths, especially in patients with severe COVID-19 as from December 2019 [1–5]. The coronavirus diseases vary from mild, self-limiting forms to more severe manifestations depending on the type of viruses involved [6, 7]. As the pandemic progressed, about 461,175,583 cases, 6,071,057 deaths, and 394,441,157 recovered cases have been reported globally [8]. The impacts of the pandemic have been felt unequally around the world, with Europe and America being highly affected, as shown by overwhelmed health systems and high death tolls [9].

The Coronavirus Disease 2019 (COVID-19) is spreading across Africa, and available data indicates that it is on the rise in Cameroon, Uganda, and other African countries [10, 11]. A third wave of the pandemic, characterised by the delta (δ) strain of the virus, has also reached parts of Africa. The first case of COVID-19 in Cameroon was identified on the 6th of March 2020 [12] and as of 6th July 2020, 320 deaths were recorded and almost 15,000 cases were confirmed [13–15]. As of the 29th of December 2021, 3,756 health personnel tested positive for COVID-19 nationwide [16], of whom two of the 45 from the South West Region of Cameroon died [17], and as the situation progressed 121,650 cases, 1,935 dead, and 117,263 recovered nationwide [8, 18]. As of 28th July 2021, 285,522 people had received the first dose of the vaccine and 53,365 the second, representing 38% consumption of the received vaccines [17].

The reference and definitive diagnosis of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection is the reverse transcription polymerase chain reaction assay (rt-PCR). Chest X-ray (CXR), although not generally considered sensitive for the detection of pulmonary abnormalities in the early stage of the disease, can be a useful diagnostic tool for monitoring the rapid progression of lung involvement in COVID-19, especially in patients admitted to intensive care units (ICUs) [19].

Many approaches have been used for the treatment of high mortality risk patients as well as other patients [20, 21]. The recovery of patients presenting with varying symptoms depends on treatment regimens administered [20], as well as the severity of the infection. The clinical spectrum of COVID-19 varies from asymptomatic presentation (Stage I) to moderate to severe states (Stages IIa and IIb) characterized by respiratory failure necessitating, mechanical ventilation and ICU support and those manifesting with critical clinical condition (Stage III), with mild to moderate disease occurs in approximately in 81% of cases [22].

Individuals of all ages are at risk for infection and severe disease. However, the probability of serious COVID-19 disease is higher in the old, those living in nursing homes or long-term care facilities, and those with chronic medical conditions [21].

In Cameroon, SARS-CoV-2 screening, hydroxychloroqine/azithromycin regimens and COVID-19 vaccines are free in all Health Districts while the ADSAK/ELIXIR COVID costs 20,000Fcfa (30.6€ or 36.3$) and is available in Catholic and Private Health Facilities across the Country. As of 8th July 2021, the following COVID-19 vaccines; Sinopharm BIBP, and Oxford–AstraZeneca were in Cameroon, as well as Janssen (Johnson & Johnson) donated by the United States Government, and the African Union [16]. A variety of face masks (FMs) are available in Pro-pharmacies in most health facilities, local shops, tailoring shops, and street vendors. The average cost of FMs was 350Fcfa (0.53€ or 0.63$); range 200 – 500Fcfa (0.31 – 0.76€ or 0.36 – 0.91$). The majority of the population using FMs, use the locally made masks/cloth masks that costs 200Fcfa (0.31€ or 0.31$). The monthly income of the population ranges between 16.65 and 72.11 € (or 19.81 and 85.81$) [23]. Conversion rates; 1€ = 655Fcfa, 1$ = 551.13Fcfa.

Cameroon is known as Africa in miniature, with variety of ethnic groups. Apart from the conflict hit areas, Cameroon is an economic hub in Central Africa with an estimated population of about 23,344,000 in 2015 [23]. Due to the pandemic, a couple of studies on COVID-19 have been carried out in Cameroon; vaccine hesitancy/acceptance [24–26], responses to COVID-19 in the educational sector [13], clinical characteristics and outcomes of patients hospitalised for COVID-19 [27, 28], COVID-19 preventive behaviours [12], as well as knowledge attitudes and practices [29, 30], but none has explored the diagnosis/treatment symptoms, face mask ownership/utilisation, preventive measures, and vaccine hesitancy amongst patients recovering from the COVID-19 infection. Thus, in this study, we aimed to establish pre- and post-COVID-19 diagnosis/treatment symptoms amongst persons who suffered from COVID-19 infection, ownership and utilisation of face masks, as well as vaccine hesitancy.

Methods

Study design and setting

A cross-sectional study was conducted from April 29th - July 4th, and August 2nd - October 30th, 2021 amongst persons who had tested positive for COVID-19. Patients who admitted having recovered from COVID-19 as confirmed by a negative control test result, were enrolled into this study. Those who consented to fill the questionnaire, were cautioned not to fill it if they had earlier filled a similar questionnaire, online. Information on pre-/post-recovery clinical symptoms were collected with the use of anonymous online as well as ‘hand-filled’ questionnaires (S1 Appendix).

Bafoussam, Douala, and Yaoundé are metropolis located respectively in the West, Littoral, and Centre regions of Cameroon, with Douala, and Yaoundé being the largest.

Study population and target sample size

The study population was persons who by chance had new technology devices and could access social media platforms, and those who were at home/work place/outpatient department (OPD) of selected hospitals. The Google© questionnaire’s link was distributed via social media: WhatsApp, LinkedIn, Facebook, Skype, and Instagram. It was also shared from door-to-door, work places and OPD of hospitals in the towns of Bafoussam, Douala, and Yaoundé. Being COVID-19 positive, adult (≥ 20 years of age) and verbal consent to participate in the study constituted the inclusion criteria.

An estimated minimum sample size of 256 per town was calculated with the CDC Epi Info 7 StatCalc, and collected by convenience sampling, considering the following characteristics: an estimated Cameroon population size of 23,344,000 in 2015 [23], an assumed frequency of persons who have recovered from COVID-19 of 50%, accepted error margin of 5%, and design effect of 2.0.

Sampling method

The study was conducted during the second wave of the COVID-19 pandemic in Cameroon. The convenience sampling technique was implored wherein participants were approached and informed of the study objectives via social media platforms, at their work places, at their door steps and OPD of hospitals. Investigators continuously posted the questionnaire together with reminders on various platforms, regularly checked incoming responses, as well as regularly checked workplaces, homes, and OPDs to collect ‘hand dropped’ questionnaires.

Data collection and analysis

Data was collected with the use of anonymous self-administered online [3, 4] and workplace/door-to-door/OPD questionnaires using Microsoft Office Excel and analysed with CDC Epi Info version 7.2. The questionnaire that consisted of 29 questions, aimed to collect information on: socio-demographic characteristics, ownership/utilisation of FMs, pre-/post-symptoms, and treatment of COVID-19, as well as opinions on COVID-19 vaccination. The survey instrument took approximately 10 minutes to complete. The validity of the questionnaire was confirmed by pre-testing in 10 participants who were excluded from the study. Based on the pre-test study, the format and wording of some questions were corrected and refined. Data from the 10 participants was used to assess internal consistency reliability using Cronbach’s alpha (α) [31–33]. The results showed adequate internal consistency reliability (with Cronbach’s α = 0.72) [31, 32].

Age groups, sex, education, and occupation were summarised as counts and percentages. Body Mass Index (BMI), age, household size, number of sleeping rooms, length of hospital stay/quarantine, were expressed as ranges and means. Analysis of variance (ANOVA) and Multinomial Logistic Regression were used to determine associations between hospitalisation/quarantination and ownership/utilisation of FMs with demographic characteristics. In order to control for confounders, the least significant independent covariates were excluded from the Multinomial Logistic Regression analysis. The following models were used:

Ownership of FM = β0 + β1Age + β2Sex + β3Marital Status + β4Education + β5Occupation + β6Family size + ε, and

Household ownership of FM/Correct wearing of FM/ = β0 + β1Age + β2Sex + β3Marital Status + β4Education + β5Occupation + β6Family size + β7Residential area + ε. Where β0 is a constant, β1, β2, β3, …, and β7 are coefficients and ε is the regression error.

The significance level was set at < 0.05.

Definition of concepts/dependent variables

Severity of COVID-19

The severity grading of COVID-19 in this study consisted of pre-/post-treatment symptoms and their duration, age (≥60 years considered riskier), and comorbidities (five; on a score of 2) with a severity grading of < 20% for asymptomatic, 20 - < 40% for mild, 40 - < 80% for moderate and ≥ 80% for severe COVID-19.

Ownership of face masks

The proportion of respondents who had at least one FM, where the numerator comprised the number of respondents surveyed with at least one FM and the denominator, the total number of respondents surveyed. Entire household ownership of FMs; the proportion of households wherein all de facto members have FMs, where the numerator comprises the number of households wherein all de facto members own FMs and the denominator, the total number of respondents surveyed.

Utilisation of face masks

The correct wearing of FMs; the proportion of respondents who correctly wore FM, where the numerator comprises the number of respondents surveyed correctly wearing FMs as recommended by the WHO [34] and the denominator, the total number of respondents surveyed. Adequate utilisation of FMs; the proportion of respondents who wore at least six or more (≥6) FMs per week, where the numerator comprises the number of respondents surveyed adequately wearing FMs and the denominator, the total number of respondents surveyed. Regular utilisation of FMs; the proportion of respondents who regularly wore their FMs, where the numerator comprises the number of respondents surveyed regularly wearing FMs and the denominator, the total number of respondents surveyed.

Knowledge related to COVID-19 symptoms

Knowledge related to symptoms of COVID-19 comprised one open-ended question with the possibility of listing 10 or more options. The options were developed by considering previous studies with a similar research theme [35]. The options were sorted in the form of yes or no; if the answer was yes/no, a score of ‘1’/‘0’ was accorded to the participant. Modified Bloom’s cut-off points were used to judge knowledge as very poor (< 20%), poor (20 - < 40%), moderate (40 - < 60%), good (60 - < 80%), and very good (≥ 80%) [7].

Practice regarding COVID-19 prevention

Prevention practices consisted of the correct and adequate wearing of FMs, and a question on preventive measures towards COVID-19 (one correct point listed by the respondent earned a score of 1 and an omission or wrong point listed earned a score of 0). Modified Bloom’s cut-off points were used to judge knowledge as very poor (< 20%), poor (20 - < 40%), moderate (40 - < 60%), good (60 - < 80%), and very good (≥ 80%) [7].

COVID-19 Vaccine hesitancy

The proportion of respondents who will not voluntarily take COVID-19 vaccine, where the numerator comprises the number of respondents who will not take the vaccine [36] and the denominator, the total number of respondents surveyed.

Ethical consideration

This study was conducted in accordance with the Helsinki Declaration [37] as well as the principles of Personal Information Protection and Electronic Documents Act [38], and cleared by the North West Regional Delegation of Public Health (Reference No: 95/ATT/NWR//RDPH/BRIGAD). Only respondents who verbally consented to the study, were allowed to participate by filling and submitting the anonymous questionnaire.

Results

Characteristics of study population

Six hundred and ninety (690) persons were logged into our Microsoft Excel sheet, from whom 25 were dropped as outliers for age, BMI, and prolonged hospitalisation. Of the 665 persons included in this study, 2,126 household residents were counted; 1,751 (82.4%) were persons 0 – 59 years old and 375 (17.6%) were persons ≥ 60 years old. Four hundred and thirty-seven (52.2%) persons were females and 318 (47.8%) were males (Table 1).

Table 1. Characteristics of study participants.

General characteristic Subclass Count (%)
Age groups (in years) ≤ 40 510 (76.7)
> 40 155 (23.3)
Mean age (x¯ ± SD) 34.00 ± 9.00
Sex Female 437 (52.2)
Male 318 (47.8)
BMI (Kg/m 2 ) Eutrophic 256 (38.5)
Overweight 233 (35.0)
Obese 176 (26.5)
Mean BMI (x¯ ± SD) 27.00 ± 4.00
Marital status Not married 390 (58.6)
Married 275 (41.4)
Education Primary 142 (21.4)
Secondary 218 (32.8)
Tertiary 305 (45.9)
Occupation Business/Private sector 118 (17.7)
Student 97 (14.6)
Unemployed 118 (17.7)
Unskilled worker 64 (9.6)
Skilled worker 268 (40.3)
Household size 1 – 4 546 (82.1)
5 – 9 119 (17.9)
Mean household size (x¯ ± SD) 3.00 ± 1.00
Number of sleeping rooms One 209 (31.4)
Two 365 (54.9)
More than two (3 - 5) 91 (13.7)
Mean number of rooms (x¯ ± SD) 1.00 ± 0.00
Comorbid condition Gastritis 202 (30.4)
Previously operated 89 (13.4)
High blood pressure 108 (16.2)
Hepatitis/Liver disease 95 (14.3)
Diabetes 50 (7.5)
Number of comorbidities None 202 (30.4)
At least one 384 (57.7)
At most two 77 (11.7)

BMI; Body Mass Index [Eutrophic (18.5 ≤ BMI ≥ 24.9), Overweight (25.0 ≤ BMI ≥ 29.9), Obese (BMI ≥ 30.0)], SD; Standard Deviation.

The mean age of the participants was 34 years (SD 9.0, range 20 – 64). Three hundred and ninety (58.6%) were singles, 308 (45.9%) were of tertiary educational status, and 268 (40.3%) were skilled workers.

Clinical profile of respondents

Pre- and post- COVID-19 diagnosis/treatment symptoms

Three hundred and ten (46.6%), 289 (43.5%), and 214 (32.2%) of the respondents presented with cough, sore throat, and tiredness, respectively (Fig 1) for a mean duration of 2.30 days (SD 2.46, range 0 – 9 days) prior to diagnosis and treatment. Fatigue/Tiredness, dry/unproductive cough, and shortness of breath were experienced for a mean duration of 3.65 days (SD 3.17, range 0 – 8) after drug administration.

Fig 1. Pre- and post-symptoms of COVID-19.

Fig 1

Two hundred and sixty-eight (40.3%) and 316 (47.5%) of the respondents, respectively, manifested with no symptoms of COVID-19 prior to testing positive and after treatment (Fig 1).

Severity and comorbidities

The severity of pre- and post-COVID-19 diagnosis and treatment are presented in Fig 2. The most common comorbidities were gastritis 202 (30.4%), high blood pressure 108 (16.2%), and hepatitis and/or other liver diseases 95 (14.3%), with 202 (30.4%) having no comorbidity and 77 (11.7%) having at most two comorbidities (Table 1).

Fig 2. Severity grading for pre- and post-COVID-19 amongst age groups.

Fig 2

Duration of hospitalisation/quarantine

The mean duration of hospitalisation and quarantine periods were, respectively, 2.95 days (SD 7.20, range 0 – 24) and 6.84 days (SD 7.00, range 0 – 28). Male respondents stayed longer in the hospital and in quarantine than females (Table 2).

Table 2. Association of hospitalisation/quarantination with respondents’ characteristics; ANOVA.
Hospitalisation (in days) Quarantination (in days)
Variable Subclass x¯ ± SD F (p – value) x¯ ± SD F (p – value)
Age (in years) ≤ 40 2.92 ± 7.20 2.0x10-2 (8.6x10-1) 6.70 ± 7.03 1.1x10° (3.0x10-1)
> 40 3.02 ± 7.12 7.35 ± 6.74
Sex Female 2.62 ± 6.84 1.5x10-1 (2.2x10-1) 6.81 ± 6.93 1.2x10-2 (9.1x10-1)
Male 3.30 ± 7.48 6.87 ± 7.02
BMI (kg/m2) Eutrophic 2.52 ± 6.79 2.8 (2.4x10-1) 6.58 ± 6.65 3.0x10-1 (5.3x10-2)
Overweight 3.30 ± 7.56 7.05 ± 6.71
Obese 3.13 ± 7.14 6.95 ± 7.74
Total 2.95 ± 7.20 6.84 ± 7.00

Bold numbers are significant p – values. BMI; Body Mass Index [Eutrophic (18.5 ≤ BMI ≥ 24.9), Overweight (25.0 ≤ BMI ≥ 29.9), Obese (BMI ≥ 30.0)]

Care, treatment and vaccination hesitancy

Patients received either the Ministry of Health’s (MOH) protocol of oral hydroxychloroquine, paracetamol, vitamin C, zinc, and azithromycin or the local remedy ADSAK/ELEXIR COVID or both. Depending on the severity and comorbidities, some patients received or added extra doses to the prescribed doses.

Five hundred and seventy-three (86.2%) of the respondents were prescribed and administered the hydroxychloroqine/Azithromycin/Paracetamol/Zinc/Vitamin C regimen, 25 (3.8%) were simply advised to go home, and 230 (34.6%) opted to supplement the MOH’s regimen with the local remedy ADSAK/ELIXIR COVID (Table 3).

Table 3. Treatment regimens for respondents.
Treatment Frequency Percent
Counselled to go home for self-quarantine 25 3.8
Hydroxychloroqine/Azithromycin/Paracetamol/Zinc/Vitamin C 573 86.2
ADSAK/ELIXIR COVID 230 34.6
Cumulative treatment
None 81 12.2
At least one treatment regimen 340 51.1
Both treatment regimens 244 36.7
Supplemented medication 260 39.1

Only 165 (24.8%) of the respondents admitted that they will accept the vaccine when it is feasible, thus yielding a COVID-19 hesitancy rate of 74% (Fig 3). From multinomial regression analysis, the odds for denying COVID-19 vaccine was higher amongst the unemployed (OR; 1.5, 95%C.I; 0.8 – 3.0), unskilled workers (OR; 1.4, 95%C.I; 0.7 – 3.0), and those residing in Bamenda and Bafoussam [(OR; 1.3, 95%C.I; 0.6 – 2.5) vs (OR; 1.2, 95%C.I; 0.6 – 2.4)], when compared with their counterparts (S3 Table in S1 File).

Fig 3. COVID-19 Vaccine hesitancy and reasons for hesitancy.

Fig 3

Ownership/Utilisation and sources of face masks

Ownership/Utilisation of face masks

Of the 665 respondents sampled, 155 (23.3%) were in households wherein all residents owned FMs (Fig 4).

Fig 4. Ownership/utilisation of face masks.

Fig 4

Two hundred and seventy-one (40.8%) of the respondents correctly wore their FMs to cover the nose, mouth, and chin, such so as to be able to breathe, while 313 (47.1%) adequately/effectively used FMs for ≥ 6 days/week (Fig 4).

Factors associated with ownership/utilisation of face masks

Multinomial logistic regression was used to test if respondent characteristics were significantly associated with face mask ownership/utilisation. The results indicated that the odds for the ownership of FMs by the entire household were higher amongst the male sex (OR; 1.1, 95%C.I; 0.7 – 1.5), married persons (OR; 1.3, 95%C.I; 0.8 – 2.0), primary school leavers (OR; 1.3, 95%C.I; 0.6 – 2.6), students as well as business operators [(OR; 1.6, 95%C.I; 0.9 – 3.1) vs (OR; 1.3, 95%C.I; 0.7 – 2.1)] and Bamenda as well as Buea [(p; <1.0x10-3, OR; 7.6, 95%C.I; 3.8 – 15.5) vs (p; <1.0x10-3, OR; 14.6, 95%C.I; 6.5 – 33.1)] (Table 4).

Table 4. Association of respondents’ characteristics with face mask ownership/utilisation.
Ownership of FM (n = 613) Entire household own FM (n = 155)
Characteristic n (%) p-value OR (95% C.I) n (%) p-value OR (95% C.I)
Age groups (in years)
≤ 40/> 40 472/141 2.6x10-1 1.5 (0.7 – 3.1) 110/45 8.7x10-1 1.0 (0.6 – 1.8)
Sex
Male/Female 286/327 4.5x10-2 0.5 (0.3 – 1.0) 76/79 9.1x10-1 1.1 (0.7 – 1.5)
Marital status
Married/Not married 253/360 2.9x10-1 0.7 (0.4 – 1.3) 68/87 2.4x10-1 1.3 (0.8 – 2.0)
Education
Secondary/Tertiary 198/283 4.1x10-1 0.7 (0.4 – 1.5) 42/89 9.6x10-1 1.0 (0.5 – 1.6)
Primary/Tertiary 132 (21.5) 9.7x10-1 1.1 (0.4 – 3.0) 24 (15.5) 5.6x10-1 1.3 (0.6 – 2.6)
Occupation
Student/Skilled worker 87/244 6.2x10-1 0.8 (0.3 – 1.9) 27/69 1.3x10-1 1.6 (0.9 – 3.1)
Unemployed/Skilled worker 108 (17.6) 7.0x10-1 0.8 (0.3 – 2.3) 16 (10.3) 4.3x10-1 0.7 (0.3 – 1.6)
Unskilled/Skilled worker 61 (9.9) 4.9x10-1 1.6 (0.4 – 6.5) 6 (3.9) 1.8x10-1 0.5 (0.2 – 1.4)
Business operator/Skilled worker 113 (18.4) 2.1x10-1 2.0 (0.7 – 4.4) 37 (23.9) 3.9x10-1 1.3 (0.7 – 2.9)
Household size
5 – 9/1 – 4 115/498 4.1x10-2 3.2 (1.1 – 9.6) 27/128 7.0x10-2 0.6 (0.3 – 1.0)
Residence
Bamenda/Yaoundé - - - 31/44 <1.0x10-3 7.6 (3.8 – 15.5)
Bafoussam/Yaoundé - - - 8 (5.2) 6.3x10-1 0.8 (0.3 – 1.9)
Buea/Yaoundé - - - 35 (22.6) <1.0x10-3 14.6 (6.5 – 33.1)
Douala/Yaoundé - - - 37 (23.9) 2.4x10-1 0.7 (0.5 – 1.2)
Correct wearing of FM (n = 271) Adequate utilisation of FM (n 313
Age groups (in years)
≤ 40/> 40 209/62 9.9x10-1 1.0 (0.7 – 1.5) 250/63 2.2x10-3 1.9 (1.3 – 2.9)
Sex
Male/Female 119/152 1.2x10-1 0.8 (0.6 – 1.1) 152/161 7.1x10-1 1.1 (0.8 – 1.4)
Marital status
Married/Not married 103/168 1.3x10-2 0.6 (0.5 – 1.0) 123/190 6.1x10-2 0.7 (0.5 – 1.0)
Education
Secondary/Tertiary 74/133 4.1x10-2 0.6 (0.4 – 1.0) 99/152 7.9x10-1 0.9 (0.6 – 1.4)
Primary/Tertiary 64 (23.6) 9.5x10-1 1.1 (0.6 – 1.8) 62 (19.8) 7.4x10-1 0.9 (0.5 – 1.6)
Occupation
Student/Skilled worker 35/114 5.5x10-1 0.8 (0.5 – 1.4) 39/149 5.0x10-4 0.4 (0.2 – 0.6)
Unemployed/Skilled worker 55 (20.3) 6.1x10-1 1.2 (0.6 – 2.1) 55 (17.6) 8.2x10-2 0.5 (0.3 – 1.1)
Unskilled/Skilled worker 25 (9.2) 9.4x10-1 1.0 (0.5 – 1.9) 29 (9.3) 8.6x10-2 0.5 (0.3 – 1.1)
Business operator/Skilled worker 42 (15.5) 2.9x10-1 0.8 (0.5 – 1.2) 41 (13.1) 1.0x10-4 0.3 (0.2 – 0.6)
Household size
5 – 9/1 – 4 49/222 6.2x10-1 1.1 (0.7 – 1.7) 60/253 8.7x10-2 1.4 (0.9 – 2.3)
Residence
Bamenda/Yaoundé 15/95 2.4x10-1 0.6 (0.3 – 1.3) 19/121 5.9x10-2 0.5 (0.3 – 1.0)
Bafoussam/Yaoundé 30 (1.1) 1.1x10-2 2.3 (1.2 – 4.6) 26 (8.3) 7.1x10-1 0.9 (0.4 – 1.7)
Buea/Yaoundé 19 (7.0) 9.3x10-1 1.0 (0.5 – 1.9) 23 (7.4) 9.7x10-1 1.0 (0.5 – 2.0)
Douala/Yaoundé 112 (41.3) 6.1x10-1 1.1 (0.8 – 1.6) 124 (39.6) 4.0x10-1 0.8 (0.6 – 1.2)

OR = Odds Ratio; C.I. = Confidence Interval; Boldface numbers indicate significant p values.

Respondents with the primary level of education (p; 9.5x10-1, OR; 1.1, 95% C.I; 0.6 – 1.8), were more likely to correctly use FMs than those with the tertiary educational status. More females had FMs than males and were less likely to correctly wear them compared to males (p; 1.2x10-1, OR; 0.8, 95% C.I; 0.6 – 1.1) (Table 4).

The reasons advanced for the irregular use of FMs from respondents’ perspective were: ‘it is hard to be consistent’ (39.7%), ‘I wear them whenever I am going outdoors’ (28.7%), and ‘it is boring/uncomfortable’ (27.2%) (Fig 5).

Fig 5. Reasons for irregular use of face masks.

Fig 5

Source of face masks

Respondents either purchased FMs, 58.8% or obtained them freely from the office/workplace 35.8%, and a gift from a relationship 35.2%, or self-made 17.3% (Table 5).

Table 5. Sources of face masks.
Source of face masks Frequency Percent
A gift from a relationship 234 35.2
Purchased from the shop/Pharmacy 238 35.8
From the office/Workplace 391 58.8
Self-made/Tailor 115 17.3

Knowledge of COVID-19 symptoms and household preventive measures against it

Knowledge of COVID-19 symptoms

Of the 10 symptoms anticipated, 21 (3.2%) of the respondents indicated ignorance, while 258 (38.8%) were informed on all 10 (S1 Table in S1 File). Four hundred and forty (66.2%) of the respondents have very good knowledge of COVID-19 symptoms, with a knowledge score of ≥80%. Participants, 40 years or less (p; 1.7x10-2, OR; 1.7, 95% C.I; 1.1 - 2.6), unskilled workers as well as business operators [(OR; 1.3, 95% C.I; 0.6 - 2.7) vs (OR; 1.2, 95% C.I; 0.7 - 2.0)], and those residing in Buea as well as Douala [(OR; 1.3, 95% C.I; 0.6 - 2.9) vs (OR; 1.1, 95% C.I; 0.7 - 1.6)], higher odds to have very good knowledge of COVID-19 symptoms when compared with their counterparts (Table 6).

Table 6. Association of respondent’s characteristics with knowledge of COVID-19 symptoms/household preventive measures of COVID-19.
Respondent’s Characteristic VG Knowledge of symptoms (n = 440) Moderate HH preventive measures (n = 222)
Age groups (in years) n (%) p-value OR (95% C.I) n (%) p-value OR (95% C.I)
≤ 40/> 40 344/96 1.7x10-2 1.7 (1.1 - 2.6) 175/47 1.2x10-1 1.4 (0.9 - 2.2)
Sex        
Male/Female 200/240 3.6x10-1 0.8 (0.6 - 1.2) 96/126 1.9x10-1 0.8 (0.6 - 1.1)
Marital status        
Married/Not married 185/255 8.0x10-1 0.9 (0.6 - 1.4) 89/133 2.7x10-1 0.8 (0.6 - 1.1)
Education        
Secondary/Tertiary 142/205 5.0x10-1 0.9 (0.6 - 1.3) 72/104 5.8x10-1 0.8 (0.6 - 1.3)
Primary/Tertiary 93 (21.1) 1.9x10-1 0.6 (0.4 - 1.2) 46 (20.7) 4.9x10-1 0.8 (0.4 - 1.5)
Occupation        
Student/Skilled worker 53/182 3.8x10-3 0.5 (0.3 - 0.8) 24/96 8.0x10-3 0.5 (0.3 - 0.8)
Unemployed/Skilled worker 75 (17.1) 6.0x10-1 0.8 (0.5 - 1.6) 36 (16.2) 2.0x10-1 0.7 (0.4 - 1.2)
Unskilled/Skilled worker 47 (10.7) 4.8x10-1 1.3 (0.6 - 2.7) 24 (10.8) 8.4x10-1 0.9 (0.5 - 1.8)
Business operator/Skilled worker 83 (18.9) 5.1x10-1 1.2 (0.7 - 2.0) 42 (18.9) 8.5x10-1 0.9 (0.6 - 1.5)
Household size        
5 – 9/1 – 4 76/364 6.0x10-1 0.9 (0.6 - 1.4) 40/182 5.1x10-1 1.7 (0.7 - 1.8)
Residence        
Bamenda/Yaoundé 21/167 4.0x10-4 0.3 (0.2 - 0.6) 9/87 1.0x10-2 0.4 (0.2 - 0.8)
Bafoussam/Yaoundé 31 (7.0) 4.5x10-2 0.5 (0.3 - 1.0) 14 (6.3) 7.8x10-2 0.5 (0.3 - 1.1)
Buea/Yaoundé 35 (7.9) 4.6x10-1 1.3 (0.6 - 2.9) 13 (5.9) 1.7x10-1 0.6 (0.3 - 1.2)
Douala/Yaoundé 186 (42.3) 6.8x10-1 1.1 (0.7 - 1.6) 99 (44.6) 7.4x10-1 1.1 (0.7 - 1.6)

OR = Odds Ratio; C.I. = Confidence Interval; VG = Very Good; HH = Household; Boldface numbers indicate significant p values.

Household preventive measures of COVID-19

Of the five preventive measures, 570 (85.7%) of the respondents pointed out to regular hand washing, 75 (11.3%) made no mention of any of the measures, while 110 (16.5%) made mention of four of the measures (S2 Table in S1 File).

Two hundred and twenty-two (8.4%) implemented moderate (≥50%) preventive measures against COVID-19. The odds of implementing COVID-19 preventive measures was higher amongst those who were 40 years or less (OR; 1.4, 95%C.I; 0.9 - 2.2), students (p; 8x10-3, OR; 0.5, 95%C.I; 0.3 - 0.8), and those residing in Bamenda (p; 1x10-2, OR; 0.4, 95%C.I; 0.2 - 0.8), when compare with those older than 40 years, skilled workers, and those residing in Yaoundé respectively (Table 6).

Discussion

Our study adds to the description of COVID-19 in Cameroon where there is a large gap in the literature. Our study revealed that; pre-/post symptoms were dry cough and tiredness, with sore throat and headache occurring more before diagnosis/treatment while shortness of breath persisted after treatment. Gastritis, high blood pressure, and hepatitis were the underlying comorbidities of COVID-19 amongst respondents. Majority of the respondents owned FMs, few households owned FMs, while the use of FMs was generally low in all aspects. Many respondents feared COVID-19 vaccines leading to a very high VH rate.

Pre- and post – COVID-19 diagnosis/treatment symptoms

Cough, tiredness, and headache occurred in patients before and after treatment. A study from Ethiopia proved that these symptoms were confirmed amongst COVID-19 cases, with other common symptoms being sore throat [27]. Fever, fatigue, and cough, however, remain the most common symptoms in many cohort studies [28, 39, 40].

Disease severity ranged from asymptomatic (41.5% vs 43.9%) to mild (28.6% vs 18.5%) to moderate (29.9% vs 37.6%) before and after treatment. This was similar to findings reported in Ethiopia [27] but different from the findings of another study in Cameroon [28]. Nearly two-thirds of the patients suffered from at least one comorbidity (57.7%), of which gastritis was the most common (30.4%). This was similar to the 29% reported in Ethiopia [27], and different from the findings of another study [41], in which it was asserted that the most common comorbidities were obesity, diabetes and hypertension. These differences may be as a result of differences in study population and study design.

The mean duration of hospitalisation and quarantine period were, respectively, 2.95 days (SD 7.20, range 0 – 24) and 6.84 days (SD 7.00, range 0 – 28). This was lower compared with mean hospitalisation of five days reported in Cameroon [28] and the 13.5 – 42 days (SD, 9.7) reported in studies elsewhere [27, 39, 40]. Recovery, however, depends on the severity of the infection as well as comorbidities. Severity seems to have dropped with time, thus leading to both little hospitalisation and quarantine periods.

Five hundred and seventy-three (86.2%) of the respondents were prescribed and administered the hydroxychloroqine/Azithromycin/Paracetamol/Zinc/Vitamin C regimen, 3.8% were counselled to go home. In a similar study, all patients received a treatment protocol with oral chloroquine, paracetamol, vitamin C, zinc, amoxicillin combined with clavulanic acid, and azithromycin. Further, some patients received anticoagulants, corticosteroids, or intravenous antibiotics, with 15% of confirmed cases undergoing non-invasive ventilation [27].

COVID-19 vaccine hesitancy/acceptance

In this study, vaccine hesitancy (VH) was 74.0% (vaccine acceptance of 24.8%) for a variety of reasons; lack of trust and fear. This was similar to the 71 - 84.6% reported amongst Cameroonians [26, 27], as well as the 74.3% COVID-19 vaccine rejection in Bosnia and Herzegovina [42], and higher than the 62.4 – 62.6% reported elsewhere in the Arab world and Jordan [43, 44]. The reasons for high VH were lack of trust in government’s decisions [26], people’s reluctance to get the vaccine, lack of dedicated health personnel to vaccination [16], the role of social media environments, perception of pharmaceutical industry, reliability and source of vaccine [25, 45]. Generally, there is a high rate (57.4%) of COVID-19 fear as reported in Cameroon [12], which has however dropped with time. The fear of COVID-19 has dropped for the following undocumented reasons; fear of vaccines, the assumption that COVID-19 is a simple flu, and lack of enough confidence in the vaccine development process [46]. Vaccine acceptance rates are 94.4 – 97% in Asia, 62.4% in the Arab world, 23.6% in Kuwait, 28.4% in Jordan, and 53.7 – 58.9% in Europe, and rates of 27.7% in Democratic Republic of Congo [43, 47].

Face mask ownership/utilisation

In this study, 155 (23.3%) respondents were in households wherein all residents owned FMs, 613 (92.2%) owned FMs, 271 (40.8%) correctly wore them, and 313 (47.1%) adequately used FMs for ≥ 6 days/week. Adherence to the correct and effective use of FMs in this study was higher compared with 1.4% reported amongst Polish Health Care Workers [48]. The differences may be due to the fact that our study had a variety of occupations, while that reported in Poland was amongst Health Care Workers only.

In another study, respondents used FMs in various occasions: 95.3% for protection against COVID-19, 90.2% used FMs in public, 53% used it when entering restricted places, 45.5% when with a suspected case and 30.7% used a mask due to fear of arrest/punishment [49]. In the course of time, the use of FM too is decreasing as many, simply say COVID-19 does not exist.

Four hundred and forty (66.2%) of the respondents have very good knowledge of COVID-19 symptoms. In another study, 58.6% had moderate knowledge about COVID-19, whereas 37.2% had good knowledge [7]. The knowledge level in this study is higher compared to the 21.9% reported in Buea – Cameroon [29] and lower compared to the 68.2% reported in a multinational study [50].

COVID-19 preventive measures

Of the five preventive measures, 570 (85.7%) of the respondents pointed out to regular hand washing, 75 (11.3%) made no mention of any of the measures, while 110 (16.5%) made mention of four of the measures. These findings were different from the adherence to barrier measures reported in Cameroon[12].

Fundamental to assessing pre-/post- COVID-19 symptoms, and ownership and utilisation rates of FMs is obtaining epidemiological data from the communities. These findings underline the need for continuous intervention programmes to enhance the prevention of the spread of COVID-19. Regular health education on COVID-19 vaccinations, and the practice of preventive measures should be encouraged. Stakeholders should try to curb vaccine hesitation by involving local scientists in the development or manufacturing process, and by dealing with conspiracies.

Strengths and limitations

Strengths

Field data were obtained online and from workplace/door-to-door/OPDs. The quality of the data collected was assured through pretesting of questionnaires to minimize bias as well as errors.

Limitations

This was a cross-sectional study, representing the snapshot of the population within the study period and does not show cause and effect since the predictor and outcome variables were measured at the same time. Data was collected through anonymous self-reporting via partly online and partly workplace/door-to-door/OPD and thus there is a possibility of various types of bias; selection/double selection bias, and recall bias. Such biases can also affect some of the responses and subsequently the results of the study. Other limitations to this study were that online respondents might not have met the inclusion criteria, FMs were not categorised into surgical, air filtering respirators or simple cloth masks.

Conclusion

In this study, we described the symptoms and severity of COVID-19 infection as well as length of hospital stay/quarantine, face mask utilisation and vaccine hesitation/acceptance amongst persons who have recovered from COVID - 19. There was a variety of symptoms with unproductive cough and fatigue as the most prevalent symptoms occurring before and after treatment. The majority of patients had no comorbidity and the commonest comorbidities were gastritis and high blood pressure. Despite the prescription of various treatment regimens, the length of stay in the hospital or quarantine was long.

Thus, the treatment of COVID-19 does not mean immediate recovery as the mild to moderate grade severity persists. Face mask availability and ownership does not mean higher utilisation. This study advocates for an intensification of COVID-19 preventive practices, as well as elaborate education on the importance of vaccination and preparation for future disease outbreaks.

Supporting information

S1 Checklist

(DOC)

S1 Appendix. Survey questionnaire.

(PDF)

S1 File. Supplementary tables.

(DOCX)

S2 File

(DOCX)

S1 Data

(XLSX)

Acknowledgments

We are thankful to the respondents who participated in this survey and to the survey teams; especially those of Douala and Yaoundé. We wish to greatly acknowledge the Central Africa Network for Tuberculosis, HIV/AIDS and Malaria (CANTAM), for inputs on data analysis and research methods.

Abbreviations

x¯

Mean

COVID-19

Coronavirus disease 2019

FM(s)

Face mask(s)

SD

Standard Deviation

VH

Vaccine hesitancy

WHO

World Health Organisation

χ2

Chi-square

Data Availability

The data used to support the findings of this study are included within the supplementary information file(s).

Funding Statement

The authors received no specific funding for this work.

References

Decision Letter 0

Muhammad Shahzad Aslam

19 Sep 2022

PONE-D-22-15424Pre- and Post-COVID-19 Diagnosis/Treatment Symptoms, Face mask Ownership/Utilisation, COVID-19 Preventive Measures, and COVID-19 Vaccine Hesitancy Amongst Patients Recovering from the COVID-19 infection in Cameroon: A Cross-Sectional StudyPLOS ONE

Dear,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. The reviewer comment has been given below.

Please submit your revised manuscript by 18th October 2022. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Muhammad Shahzad Aslam, Ph.D.,M.Phil., Pharm-D

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Line 37, Your study period is April - July, and August - October 2021 but you however present 2022 data in lines 58 and 69. Kindly review

In line 99 where you mention the aim of the study, you don't talk about Diagnosis/treatment symptoms but emphasize pre and post COVID 19 Symptoms. It is important to be uniform in the presentation of information to ease comprehension.

The introduction section does not cleary reveal the rationale of your study. Do well to bring our the rationale of this study in the introduction section

Your study population and setting section not very clear, Kindly make this section clearer. Line 109, How did you ensure participants targeted online through various social media platforms met all your inclusion criteria (i.e infection history, actual current location, and country (your questionnaire doesn't capture information on the town, region, or city), and met the age requirements)

Line 121, Kindly clarify the sampling methods used. what is your rationale behind the selection of particular participants?

Since you collected data both physically and through Social media, it will be interesting to present analyses for respondents by channel of response (physical and social Media), as this might have some correlation with outcomes.

Line 237, Figure 3 showing analysis of vaccine hesitancy is missing

Line 332 - 333, You mention vaccine hesitance was for a variety of reasons and go ahead to site just two reasons. Good elaboration on the various objectives in your discussion section. I recommend you do the same for Vaccine hesitancy

Reviewer #2: 1. The topic is interesting but the author has raise a lot of concepts that he could not full address. To talk about Pre- and Post-COVID-19 Diagnosis, Treatment, Symptoms, Face mask

Ownership/Utilisation, COVID-19 Preventive Measures, and COVID-19 Vaccine Hesitancy is too much that can be full addressed by your finding. consider reducing the scope of your topic.

2. Your background doesn't showcase the problem you are addressing and the figures presented are outdated.

3. Your interpretation of OR are not correct. When your confidence interval crosses 1 its means there is no relationship.

4. All concepts handle under your study should be clearly discussed and probably under different paragraphs

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Charles Njumkeng

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PONE-D-22-15424_CN.pdf

PLoS One. 2023 Jan 20;18(1):e0280269. doi: 10.1371/journal.pone.0280269.r003

Author response to Decision Letter 0


30 Sep 2022

We wish to immensely thank the Editor and Reviewers for the comments and pointers.

We have objectively responded to the comments and recommendations made in the 'Response to Reviewers'.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Muhammad Shahzad Aslam

28 Oct 2022

PONE-D-22-15424R1Pre- and Post-COVID-19 Diagnosis/Treatment Symptoms, Face mask Ownership/Utilisation, COVID-19 Preventive Measures, and COVID-19 Vaccine Hesitancy Amongst Patients Recovering from the COVID-19 infection in Cameroon: A Cross-Sectional StudyPLOS ONE

Dear Dr. Cho,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Dec 12 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Muhammad Shahzad Aslam, Ph.D.,M.Phil., Pharm-D

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This article is now fit for publishing as all the concerns raised have been addressed by the authors have.

Reviewer #2: 1. The author did not response to my suggestion of reshaping the topic to make it more attractive and better support the finding. It will be good for him to provide clear justification why the topic should be maintained as it is.

2. Author did not rephrase the sentence “symptoms severity range from asymptomatic to moderate” in the abstract. Asymptomatic means no symptom. Kindly indicate the symptoms to ease understanding of which was severe and which was mild

3. Line 103: The author has not explained how he ensured that those surveyed from April to July 4 were not surveyed in August since the study was conducted in two sections. What is a repeated survey?

4. Line 161, Author talk about wearing of MF correctly but he has not explained how he assessed this for those who participate in the survey by responding online questionnaire

5. Line 206 and 207: Please check this out it is not possible for the number of persons (665)enrolled to be lower than the number households(2,126)

6. Line 261-264 the use of more likely indicate association, which is not consistent with your p-values. The still need to be addressed. Same with line 270

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Nsai Frankline Sanyuy

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Jan 20;18(1):e0280269. doi: 10.1371/journal.pone.0280269.r005

Author response to Decision Letter 1


30 Oct 2022

Face mask Ownership/Utilisation and COVID-19 Vaccine Hesitancy Amongst Patients Recovering from COVID-19 in Cameroon: A Cross-sectional Study

Attachment

Submitted filename: Response to Review.docx

Decision Letter 2

Muhammad Shahzad Aslam

28 Nov 2022

PONE-D-22-15424R2Face mask Ownership/Utilisation and COVID-19 Vaccine Hesitancy Amongst Patients Recovering from COVID-19 in Cameroon: A Cross-sectional StudyPLOS ONE

Dear,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. The strength and limitation of study must present after discussion. So, please move its current place. Please explain more about limitation of the study to explain the potential bias in the study.

There is no study implication given. Please give in detail at the end.

Please provide the response rate of the study.

Please provide study information sheet as supplementary file.

Please explain in details about the query of the reviewer "Line 206 and 207: Please check this out it is not possible for the number of persons (665)

enrolled to be lower than the number households (2,126)."

Please explain in details on comments given by reviewer. The peer reviewer are not satisficed with comments and does not explain well. Please include your questionnaire inside the manuscript and explain all comments in manuscript in detail.

Please provide strobe statement and strobe checklist as supplementary file.

Please provide raw data as well as supplementary file.

Please submit your revised manuscript by 26 December 2022. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Muhammad Shahzad Aslam, Ph.D.,M.Phil., Pharm-D

Academic Editor

PLOS ONE

PLoS One. 2023 Jan 20;18(1):e0280269. doi: 10.1371/journal.pone.0280269.r007

Author response to Decision Letter 2


1 Dec 2022

Line 206 and 207: Please check this out it is not possible for the number of persons (665) enrolled to be lower than the number households (2,126).

We interviewed one person per household; only one who had suffered from COVID-19 and got treated. In the questionnaire, we enquired the number of persons living in the household (Question 7 on the questionnaire).

Thus, the statement is, 665 persons/household included in the study, 2,126 de facto household residents were counted. This implies that 2,126 household residents were counted in the 665 households. Thus, 1,461 (2,126 - 665) persons were exposed.

Due to adjustments, the lines have changed to lines 203 – 204.

The above issue and others have been raised and we have objectively provided answers.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 3

Muhammad Shahzad Aslam

26 Dec 2022

Face mask Ownership/Utilisation and COVID-19 Vaccine Hesitancy Amongst Patients Recovering from COVID-19 in Cameroon: A Cross-sectional Study

PONE-D-22-15424R3

Dear Dr. Cho,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Muhammad Shahzad Aslam, Ph.D.,M.Phil., Pharm-D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: All comments have been addressed by the authors as requested. There are no further comments to present to the authors

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Nsai Frankline Sanyuy

**********

Acceptance letter

Muhammad Shahzad Aslam

6 Jan 2023

PONE-D-22-15424R3

Face mask Ownership/Utilisation and COVID-19 Vaccine Hesitancy Amongst Patients Recovering from COVID-19 in Cameroon: A Cross-sectional Study

Dear Dr. Cho:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Muhammad Shahzad Aslam

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist

    (DOC)

    S1 Appendix. Survey questionnaire.

    (PDF)

    S1 File. Supplementary tables.

    (DOCX)

    S2 File

    (DOCX)

    S1 Data

    (XLSX)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Attachment

    Submitted filename: PONE-D-22-15424_CN.pdf

    Attachment

    Submitted filename: Response to Reviewers.docx

    Attachment

    Submitted filename: Response to Review.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    The data used to support the findings of this study are included within the supplementary information file(s).


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES